SAR directed design and synthesis of novel β(1-4)-Glucosyltransferase inhibitors and Their In vitro inhibition studies
作者:Asish K Bhattacharya、Florian Stolz、Jürgen Kurzeck、Wolfgang Rüger、Richard R Schmidt
DOI:10.1016/s0968-0896(01)00371-6
日期:2002.4
This paper describes SAR directed design and synthesis of novel beta(1-4)-glucosyltransferase (BGT) inhibitors. The designed inhibitors 1-5 provide conformational mimicry of the transition-state in glucosyltransfer reactions. The compounds were tested for in vitro inhibitory activity against (BGT) and the inhibition kinetics were examined. Three of the designed molecules were found to be potential inhibitors of BGT having IC50 values in micromolar (muM) range. Useful structure-activity relationships were established, which provide guidelines for the design Of future generations of inhibitors of BGT. (C) 2002 Elsevier Science Ltd. All rights reserved.
[EN] CREATINE PHOSPHATE PRODRUGS, COMPOSITIONS AND USES THEREOF<br/>[FR] PROMÉDICAMENTS DE PHOSPHATE DE CRÉATINE, COMPOSITIONS ET UTILISATIONS DE CEUX-CI
申请人:XENOPORT INC
公开号:WO2007146085A2
公开(公告)日:2007-12-21
[EN] Membrane permeable prodrugs of creatine phosphate, pharmaceutical compositions comprising membrane permeable prodrugs of creatine phosphate, and methods of treating diseases such as ischemia, heart failure, and neurodegenerative disorders comprising administering prodrugs of creatine phosphate or pharmaceutical compositions thereof are disclosed. [FR] La présente invention concerne des promédicaments à perméabilité de membrane de phosphate de créatine, des compositions pharmaceutiques comprenant des promédicaments à perméabilité de membrane de phosphate de créatine, et des procédés de traitement de maladies telles que l'ischémie, l'insuffisance cardiaque, et des troubles neurodégénératifs comprenant l'administration de promédicaments de phosphate de créatine ou des compositions pharmaceutiques de ceux-ci.